Ticagrelor

Ticagrelor is sold under the brand name Brilinta. It is the first approved reversible oral antiplatelet agent. Its molecular formula is C23H28F2N6O4S and molecular weight is 522.567 g/mol. Ticagrelor was approved for medical use in the European Union in December 2010 and in the United States in July 2011.The Drug Controller General of India (DCGI), based on the New Drug Advisory Committee's (NDAC) recommendations granted its approval in May 2012 for marketing Brilinta (Ticagrelor) tablets in India.

Structure: - Ticagrelor is a triazolopyrimidine that is an adenosine isostere, the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. Ticagrelor is a member of triazolopyrimidines, an organofluorine compound, an aryl sulfide, a secondary amino compound and a hydroxyether.

Ticagrelor is an antiplatelet medicine. It makes your blood flow through your veins more easily. This means your blood will be less likely to make a dangerous blood clot. 

Ticagrelor is a P2Y12 platelet inhibitor used in patients with a history of myocardial infarction or with acute coronary syndrome (ACS) to prevent future myocardial infarction, stroke and cardiovascular death.

Ticagrelor is used along with low-dose aspirin to help prevent heart attack and stroke in people with a history of heart disease, stroke, or at increased risk for heart disease or stroke (for example, due to diabetes, history of transient ischemic attack-TIA). It may also prevent blood clots after certain heart surgeries (such as stent placement).

Ticagrelor has a plasma half-life of approximately 8 hours, while the active metabolite has a plasma half-life of approximately 12 hours.

Mechanism of action:-

Ticagrelor is a P2Y12 receptor antagonist, which means it inhibits platelet activation and aggregation by reversibly interacting with the platelet P2Y12 adenosine diphosphate (ADP) receptor to prevent signal transduction.

The P2Y12 receptor couples with G? and other Gi proteins which inhibit adenylyl cyclase Gi mediated signalling also activates PI3K, Akt, Rap1b, and potassium channels. The downstream effects of these activities mediate hemostasis and lead to platelet aggregation. 

Antagonism of the P2Y12 receptor reduces development of occlusive thromboses, which can reduce the risk of myocardial infarction and ischemic stroke.

Applications:- 

Ticagrelor is used for prevention of heart attack and stroke. It decreases the chances of having another heart attack or stroke.Clinical studies have been shown to be safer and even reduce rate of death from vascular events as compared head to head with clopidogrel.It may also prevent blood clots after certain heart surgeries (such as stent placement) It keeps blood flowing smoothly in your body.

To enquire for many more impurities Ticagrelor of follow the link given below:

https://www.simsonpharma.com/product/ticagrelor